Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

82.80
Delayed Data
As of Aug 11
 -2.35 / -2.76%
Today’s Change
31.99
Today|||52-Week Range
91.77
+93.87%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$5.1B

Company Description

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Contact Information

Ultragenyx Pharmaceutical, Inc.
60 Leveroni Court
Novato California 94949
P:(415) 483-8800
Investor Relations:
(415) 475-6876

Employees

Shareholders

Mutual fund holders85.48%
Other institutional19.90%
Individual stakeholders13.78%

Top Executives

Emil D. KakkisPresident, Chief Executive Officer & Director
Shalini SharpChief Financial Officer & Executive Vice President
Dennis Karl HuangChief Technical Operations Officer & Senior VP
Camille L. BedrosianChief Medical Officer & Executive Vice President
Thomas Richard KassbergChief Business Officer & Executive Vice President